

# Assessing the safety and effectiveness of a biopsy instrument when sampling tumours in the urinary bladder

<b>Submission date</b> 30/07/2020	<b>Recruitment status</b> Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/09/2020	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 25/09/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Muscle-invasive bladder cancer is cancer that has spread into the muscle wall of the bladder. Treatment is based on taking a biopsy (sample) of the tumor. Today a biopsy is retrieved by a surgical procedure called transurethral resection under anesthetic before treatment with either neoadjuvant chemotherapy (drug treatment) and cystectomy (removal of the bladder) or cystectomy only. The aim of this study is to investigate a new biopsy device (Urodrill) for diagnosing muscle-invasive bladder cancer under local anesthetic.

### Who can participate?

Patients aged 18 and over with suspected muscle-invasive bladder cancer

### What does the study involve?

Participants are randomly allocated to undergo either standard transurethral resection or an endoscopic biopsy under local anesthetic with the Urodrill instrument.

### What are the possible benefits and risks of participating?

The benefit from participating is a chance to avoid a transurethral resection of the bladder tumor under anesthetic and instead have a local anesthetic procedure in the outpatient clinic. The risks are related to biopsying the tumor in the conventional and experimental group mainly relating to bleeding after the procedure and perforation.

### Where is the study run from?

Skåne University Hospital (Sweden)

### When is the study starting and how long is it expected to run for?

November 2019 to June 2026

### Who is funding the study?

Skåne Region Health Care Fund for Development and Innovation (Sweden)

Who is the main contact?  
Prof. Fredrik Liedberg  
fredrik.liedberg@med.lu.se

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Fredrik Liedberg

**ORCID ID**  
<https://orcid.org/0000-0001-8193-0370>

**Contact details**  
Department of Urology  
Lund University  
Skåne University Hospital  
Jan Waldenströmsgata 5  
Malmö  
Sweden  
SE-205 02  
+46 (0)40 33 19 41  
fredrik.liedberg@med.lu.se

## Additional identifiers

**Protocol serial number**  
CIV-20-05-032908

## Study information

**Scientific Title**  
Safety and efficacy of the EndoDrill® Uro X biopsy instrument when sampling tumours in the urinary bladder

**Acronym**  
Urodrill study

**Study objectives**  
Time from radiological suspicion to start of definitive treatment for muscle-invasive bladder cancer can be decreased by using the Urodrill pathway.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**

Approved 18/03/2020, National Ethical Committee (Etikprövningsmyndigheten, Box 2110, 750 02 Uppsala, Sweden; +46 (0)10 475 08 00; [registrator@etikprovning.se](mailto:registrator@etikprovning.se)), ref: 2019-06537

## **Study design**

Randomized controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Diagnostic

## **Health condition(s) or problem(s) studied**

Bladder cancer

## **Interventions**

Method of randomisation: closed envelopes

Conventional arm: standard transurethral resection

Experimental arm: endoscopic biopsy under local anesthesia with the Urodrill instrument

## **Intervention Type**

Procedure/Surgery

## **Primary outcome(s)**

Time from radiological suspicion of MIBC to start of definitive treatment for MIBC (neoadjuvant chemotherapy and/or cystectomy): measured using prospective registration at day for radiological report stating suspicion of MIBC to starting day of neoadjuvant chemotherapy, or cystectomy for those operated without neoadjuvant chemotherapy by prospective registration

## **Key secondary outcome(s)**

1. Complications from the EndoDrill biopsy procedure assessed by a structured telephone interview 2 weeks after the procedure
2. Proportion of patients with MIBC that the EndoDrill® Uro X -instrument failed to detect, but diagnosed with ordinary TURBT, measured using pathology at [at secondary procedure with TURBT for those in the experimental arm without verification of MIBC and with MIBC verified by TURBT
3. Proportion of patients with successful molecular classification based on RNA sequencing performed in real time with 6 weeks of sampling in both arms
4. Cancer-specific survival (CSS) measured using chart review at 24 months after initiating definitive treatment for MIBC
5. Overall proportion of patients who correctly followed the protocol and were staged as MIBC in the intervention arm, measured using chart review within 3 months of inclusion
6. Cost-effectiveness based on EQ5D5L at baseline and 2 weeks
7. Quality of life measured using FACT-G questionnaire preoperatively and FACT-VCI at 12 months
8. Adverse events assessed during a phone interview by a research nurse 2 weeks after the procedures
9. Sensitivity and specificity for CT-urography and MRI respectively to accurately determine

muscle-invasive bladder cancer compared to the outcome of the combined measure of biopsy and cystectomy specimen, measured using sensitivity calculations compared to pathology within 3 months of inclusion

**Completion date**

30/06/2026

**Reason abandoned (if study stopped)**

Objectives no longer viable

## Eligibility

**Key inclusion criteria**

1. Provision of written informed consent
2.  $\geq 18$  years of age
3. Patients attending participating urology departments for haematuria investigation and CT-urography suspicious of muscle-invasive bladder cancer

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Patients unable or unwilling to undergo EndoDrill biopsy
2. Bleeding diathesis prohibiting EndoDrill biopsies
3. Ongoing immunosuppression (except corticosteroids in moderate doses, less than 10 mg prednisolone or equivalent daily)
4. Patients not suitable/fit for radical treatment for MIBC
5. Pregnancy

**Date of first enrolment**

01/10/2020

**Date of final enrolment**

30/06/2026

## Locations

**Countries of recruitment**

Sweden

**Study participating centre**  
**Skånes Universitetssjukhus**  
Department of Urology  
Jan Waldenströms gata 7  
Malmö  
Sweden  
205 02

## Sponsor information

**Organisation**  
Skåne University Hospital

**ROR**  
<https://ror.org/02z31g829>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
Skåne Region Health Care Fund for Development and Innovation

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated in the present study will not be stored in a publicly available repository due to the small study size and mainly descriptive data.

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Other publications</a>	Prior feasibility study results	02/06/2023	17/09/2025	Yes	No